PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
405203 100 µg 45€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405204 500 µg 156€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified

Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  2. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  3. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  4. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  5. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  6. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  7. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  8. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  9. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  10. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  11. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  12. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  13. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  14. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  15. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  16. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  17. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  18. Gniffke EP, et al. 2020. medRxiv. . PubMed
  19. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  20. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  21. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  22. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  23. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  24. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  25. Biswas S, et al. 2021. Nature. 591:464. PubMed
  26. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  27. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  28. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  29. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  30. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  31. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  32. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  33. Im S, et al. 2016. Nature. 537:417-421. PubMed
  34. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  35. Cao Y, et al. 2022. Nature. :. PubMed
  36. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  37. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  38. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  39. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  40. Schanda N, et al. 2021. Cells. 10:. PubMed
  41. Köchl R, et al. 2020. Elife. 9:00. PubMed
  42. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  43. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  44. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  45. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  46. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  47. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  48. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  49. Cao Y, et al. 2022. Nature. 602:657. PubMed
  50. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  51. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  52. Weiß S, et al. 2020. medRxiv. . PubMed
  53. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  54. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  55. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  56. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  57. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  58. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  59. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  60. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  61. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  62. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  63. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  64. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  65. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  66. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  67. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  68. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  69. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  70. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  71. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  72. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  73. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  74. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  75. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  76. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  77. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  78. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  79. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  80. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  81. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  82. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  83. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  84. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  85. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  86. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  87. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  88. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  89. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  90. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  91. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  92. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  93. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  94. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  95. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  96. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  97. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  98. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  99. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  100. Dan JM, et al. 2021. Science. :371. PubMed
  101. He X, et al. 2014. J Immunol. 193:1314. PubMed
  102. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  103. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  104. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  105. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  106. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  107. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  108. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  109. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  110. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  111. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  112. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  113. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  114. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  115. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  116. Wells DK, et al. 2020. Cell. 183:818. PubMed
  117. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  118. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  119. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  120. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  121. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  122. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  123. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  124. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  125. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  126. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  127. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  128. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  129. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  130. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  131. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed
  132. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06.17.2019

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account